AbbVie CEO Leads US$1.4bn Manufacturing Expansion
AbbVie is investing £1.1bn (US$1.4bn) in a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, marking the company's largest capital investment to date. The decision represents a significant strategic move by the pharmaceutical giant to expand its US manufacturing footprint into a new region.
The campus will integrate advanced manufacturing and laboratory technologies as well as AI to support the production of immunology, neuroscience and oncology medicines. AbbVie expects the facility to create 734 jobs, including engineers, scientists, manufacturing operators and laboratory technicians.
The first phase of construction will include small volume parenteral drug product manufacturing facilities, next-generation laboratories, a warehouse, administrative offices and employee wellness facilities. Small volume parenterals are sterile injectable pharmaceutical products with volumes typically less than 100ml, including vials, prefilled cartridges and prefilled syringes containing medicines for injection or infusion.
Robert A. Michael, Chairman and CEO of AbbVie, says: "Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States. By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina."
Strategic location drives expansion
This campus is AbbVie's first major investment in North Carolina. The company says the site location was selected due to the strength of the region's workforce and its ability to support future expansion, positioning the facility near North Carolina's Research Triangle Park.
Other US companies which have invested heavily in North Carolina recently include Siemens, which completed construction of a train manufacturing and rail services facility in Lexington in 2024, and Toyota, which held an opening ceremony for a battery manufacturing facility in 2025.
Josh Stein, Governor of North Carolina, says: "We welcome AbbVie's major investment to North Carolina. When you combine our world-renowned research and innovation with a strong, thriving life sciences hub, North Carolina quickly becomes the premier location for biopharmaceutical companies to do business."
Commitment to US investment
This project is part of the company's £79bn (US$100bn) commitment to US R&D and capital investments, including manufacturing, over the next decade. AbbVie currently employs approximately 29,000 people in the US, including over 6,000 at its manufacturing campuses.
According to data from McKinsey, the biopharmaceutical industry has an annual growth rate of roughly 6%, and a 2025 McKinsey report suggests that existing production capacities are struggling to meet demand. Biopharmaceutical manufacturing is often a sophisticated, variable and fragile process, with manufacturing sequences involving multiple steps with complex interactions and interdependencies across end-to-end processes.
McKinsey's report says that AI and advanced analytics could be a "shot in the arm" for the sector, which could help sites optimise existing resources and enhance throughput to meet the rising demand for large molecules.
